TGFB1 and arthritic joint disease: They found that co-treatment with anti-TGF-β1, anti-IL-6 and anti-IL-17 antibody reduced the severity of arthritis significantly more than the inhibition of single cytokines in Borellia-vaccinated and challenged mice did [52].